Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2016

01.02.2016 | 2015 SSAT Plenary Presentation

A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer

verfasst von: Olga Kantor, Mark S. Talamonti, Susan J. Stocker, Chi-Hsiung Wang, David J. Winchester, David J. Bentrem, Richard A. Prinz, Marshall S. Baker

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Previous studies examining short- and long-term outcomes of pancreaticoduodenectomy with vascular resection for pancreatic adenocarcinoma have not graded perioperative complication severity. These studies may provide incomplete assessments of the efficacy of vascular resection. In the current study, we evaluated 36 patients who had pancreaticoduodenectomy with major vascular resection. These were matched 1:3 by tumor stage and age to patients who had pancreaticoduodenectomy without vascular resection. Charts were reviewed to identify all complications and 90-day readmissions. Complications were graded as either severe or minor adverse postoperative outcomes, taking into account the total length of stay. There were no statistical differences in patient demographics, comorbidities, or symptoms between the groups. Patients who had vascular resection had significantly increased rates of severe adverse postoperative outcomes, readmissions, lengths of hospital stay, as well as higher hospital costs. Hypoalbuminemia and major vascular resection were independent predictors of severe adverse postoperative outcomes. On multivariate Cox-regression survival analysis, patients who had vascular resection had decreased recurrence-free (12 vs. 17 months) and overall (17 vs. 29 months) survival. Major vascular resection was a predictor of mortality, may be an independent prognostic factor for survival, and may warrant incorporation into future staging systems.
Literatur
1.
Zurück zum Zitat Worni M, Castleberry AW, Clary BM, Gloor B, Carvalho E, Jacobs DO, Pietrobon R, Scarborough JE, White RR. Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg 2013;148(4):331-8.CrossRefPubMed Worni M, Castleberry AW, Clary BM, Gloor B, Carvalho E, Jacobs DO, Pietrobon R, Scarborough JE, White RR. Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg 2013;148(4):331-8.CrossRefPubMed
2.
Zurück zum Zitat Banz VM, Croagh D, Coldham C, Taniere P, Buckels J, Mayer D, Muiesan P, Bramhall S, Mirza DF. Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. Eur J Surg Oncol 2012;38(1):72-9.CrossRefPubMed Banz VM, Croagh D, Coldham C, Taniere P, Buckels J, Mayer D, Muiesan P, Bramhall S, Mirza DF. Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. Eur J Surg Oncol 2012;38(1):72-9.CrossRefPubMed
3.
Zurück zum Zitat Hwang JW, Kim SC, Song KB, Yoon JH, Nam JS, Lee JS, Park KM, Lee YJ. Significance of radiologic location and extent of portal venous involvement on prognosis after pancreatic adenocarcinoma. Pancreas 2015;44(4):665-71.CrossRefPubMed Hwang JW, Kim SC, Song KB, Yoon JH, Nam JS, Lee JS, Park KM, Lee YJ. Significance of radiologic location and extent of portal venous involvement on prognosis after pancreatic adenocarcinoma. Pancreas 2015;44(4):665-71.CrossRefPubMed
4.
Zurück zum Zitat Jahromi AH, Jaferimehr E, Dabbous HM, Chu Q, D’Agostino H, Shi R, Wellman GP, Zibari GB, Shokouh-Amiri H. Curative resection of pancreatic adenocarcinoma with major venous resection/repair is safe procedure but will not improve survival. JOP 2014;15(5):433-41. Jahromi AH, Jaferimehr E, Dabbous HM, Chu Q, D’Agostino H, Shi R, Wellman GP, Zibari GB, Shokouh-Amiri H. Curative resection of pancreatic adenocarcinoma with major venous resection/repair is safe procedure but will not improve survival. JOP 2014;15(5):433-41.
5.
Zurück zum Zitat Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935-49.CrossRefPubMed Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935-49.CrossRefPubMed
6.
Zurück zum Zitat Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10(8):1106-15.CrossRefPubMed Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10(8):1106-15.CrossRefPubMed
7.
Zurück zum Zitat Menon VG, Puri VC, Annamalai AA, Tuli R, Nissen NN. Outcomes of vascular resection in pancreaticoduodenectomy: single-surgeon experience. Am Surg 2013;79(10):1064-7.PubMed Menon VG, Puri VC, Annamalai AA, Tuli R, Nissen NN. Outcomes of vascular resection in pancreaticoduodenectomy: single-surgeon experience. Am Surg 2013;79(10):1064-7.PubMed
8.
Zurück zum Zitat Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, Imber CJ, UK Vascular Resection in Pancreatic Cancer Study Group. Portal vein resection in borderline resectable pancreatic cancer: A United Kingdom multicenter study. J Am Coll Surg 2014;218(3):401-11.CrossRefPubMed Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, Imber CJ, UK Vascular Resection in Pancreatic Cancer Study Group. Portal vein resection in borderline resectable pancreatic cancer: A United Kingdom multicenter study. J Am Coll Surg 2014;218(3):401-11.CrossRefPubMed
9.
Zurück zum Zitat Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer DG, McCann RL, Pappas TN, Tyler DS, Scarborough JE. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program Database. Ann Surg Oncol 2012;19(13):4068-77.CrossRefPubMed Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer DG, McCann RL, Pappas TN, Tyler DS, Scarborough JE. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program Database. Ann Surg Oncol 2012;19(13):4068-77.CrossRefPubMed
10.
Zurück zum Zitat Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 2005;8(5):377-84.CrossRefPubMed Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 2005;8(5):377-84.CrossRefPubMed
11.
Zurück zum Zitat Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250(2):187-96.CrossRefPubMed Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250(2):187-96.CrossRefPubMed
12.
Zurück zum Zitat Baker MS, Sherman KL, Stocker SJ, Hayman AV, Bentren DJ, Prinz RA, Talamonti MS. Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: Defining quality for pancreaticoduodenectomy. J Surg Oncol 2014;110(4):400-6.CrossRefPubMed Baker MS, Sherman KL, Stocker SJ, Hayman AV, Bentren DJ, Prinz RA, Talamonti MS. Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: Defining quality for pancreaticoduodenectomy. J Surg Oncol 2014;110(4):400-6.CrossRefPubMed
13.
Zurück zum Zitat Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, Jin C. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol 2014;40(4):371-8.CrossRefPubMed Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, Jin C. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol 2014;40(4):371-8.CrossRefPubMed
14.
Zurück zum Zitat Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systemic review. J Gastrointest Surg 2010;14(9):1442-52.CrossRefPubMed Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systemic review. J Gastrointest Surg 2010;14(9):1442-52.CrossRefPubMed
15.
Zurück zum Zitat Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoegger Y, Buchler MW, Weitz J. Arterial resection during pancreatectomy for pancreatic cancer: A systemic review and meta-analysis. Ann Surg 2011;254(6):882-93.CrossRefPubMed Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoegger Y, Buchler MW, Weitz J. Arterial resection during pancreatectomy for pancreatic cancer: A systemic review and meta-analysis. Ann Surg 2011;254(6):882-93.CrossRefPubMed
16.
Zurück zum Zitat Müller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, Schied BM, Büchler MW. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 2008;13(4):784-92.CrossRef Müller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, Schied BM, Büchler MW. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 2008;13(4):784-92.CrossRef
17.
Zurück zum Zitat Mbah N, Brown RE, St Hill CR, Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Impact of post-oeprative complications on quality of life after pancreatectomy. JOP 2012;13(4):387-93.PubMed Mbah N, Brown RE, St Hill CR, Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Impact of post-oeprative complications on quality of life after pancreatectomy. JOP 2012;13(4):387-93.PubMed
18.
Zurück zum Zitat Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, Ko CY, Bentrem DJ. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260(2);372-7.CrossRefPubMed Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, Ko CY, Bentrem DJ. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260(2);372-7.CrossRefPubMed
19.
Zurück zum Zitat Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012;118:3801-11.PubMedCentralCrossRefPubMed Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012;118:3801-11.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M, Jaeck D. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg 2007;142(2):172-9.CrossRefPubMed Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M, Jaeck D. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg 2007;142(2):172-9.CrossRefPubMed
21.
Zurück zum Zitat Mathur A, Ross SB, Luberice K, Kurian T, Vice M, Toomey P, Rosemurgy AS. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg 2014;80(4):353-60.PubMed Mathur A, Ross SB, Luberice K, Kurian T, Vice M, Toomey P, Rosemurgy AS. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg 2014;80(4):353-60.PubMed
22.
Zurück zum Zitat Dusch N, Weiss C, Ströbel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 2014;18(4):674-81.CrossRefPubMed Dusch N, Weiss C, Ströbel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 2014;18(4):674-81.CrossRefPubMed
23.
Zurück zum Zitat Merkow RP, Billimoria KY, Bentrem DJ, Pitt HA, Winchester DP, Posner MC, Ko CY, Pawlik TM. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol 2014;21(4):1067-74.CrossRefPubMed Merkow RP, Billimoria KY, Bentrem DJ, Pitt HA, Winchester DP, Posner MC, Ko CY, Pawlik TM. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol 2014;21(4):1067-74.CrossRefPubMed
25.
Zurück zum Zitat Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008;15(12):3521-31.CrossRefPubMed Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008;15(12):3521-31.CrossRefPubMed
26.
Zurück zum Zitat O’Rielly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, D’Angelica M, Kurtz RC, Abou-Alfa GK, Kimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014;260(1):142-8.CrossRef O’Rielly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, D’Angelica M, Kurtz RC, Abou-Alfa GK, Kimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014;260(1):142-8.CrossRef
27.
Zurück zum Zitat Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FULFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19(3)266-74.PubMedCentralCrossRefPubMed Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FULFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19(3)266-74.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnel EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernandex-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261(1):12-7.PubMedCentralCrossRefPubMed Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnel EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernandex-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261(1):12-7.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalia EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 2012;19(6):2045-53.CrossRefPubMed Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalia EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 2012;19(6):2045-53.CrossRefPubMed
Metadaten
Titel
A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer
verfasst von
Olga Kantor
Mark S. Talamonti
Susan J. Stocker
Chi-Hsiung Wang
David J. Winchester
David J. Bentrem
Richard A. Prinz
Marshall S. Baker
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2016
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2957-2

Weitere Artikel der Ausgabe 2/2016

Journal of Gastrointestinal Surgery 2/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.